Last reviewed · How we verify
Effect of Proton Pump Inhibitor and Mosapride on Acid Pocket in Gastroesophageal Reflux Disease
The gastric acid pocket is believed to be the reservoir from which acid reflux events originate. The risk for acidic reflux is mainly determined by the position of the gastric acid pocket. Little is known about how changes in position and size of the acid pocket contribute to the therapeutic effect of proton pump inhibitors(PPI) plus mosapride in patients with gastroesophageal reflux disease. Investigators will conduct a prospective randomized, single blind and placebo-controlled clinical trial to evaluate the hypothesis that mosapride affecting gastric motility might reduce gastro-esophageal reflux by changing the acid pocket position and size.
Details
| Lead sponsor | Gangnam Severance Hospital |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 30 |
| Start date | 2016-12 |
| Completion | 2018-07 |
Conditions
- Gastroesophageal Reflux Disease
Interventions
- Administration of study drug (esomeprazole, mosapride)
- Administration of study drug (esomeprazole, placebo tablet)
- upper endoscopy, scintigraphy
Primary outcomes
- Size(cm2) of the acid pocket between PPI+placebo group and PPI+mosapride group — After 4weeks of drug treatment(PPI+placebo vs. PPI + mosapride)
The size of the acid pocket will be determined by drawing an area of interest over the acid pocket in the proximal stomach in images(scintigraphy) taken at 10-minute intervals. - Location(cm) of the acid pocket between PPI+placebo group and PPI+mosapride group — After 4weeks of drug treatment(PPI+placebo vs. PPI + mosapride)
Measurements of the distances between the acid pocket and the diaphragm will be make through a straight line in a planar posterior view of the stomach in images(scintigraphy)